Tech Company Financing Transactions
Savara Pharmaceuticals Funding Round
On 6/11/2014, Savara Pharmaceuticals raised $4.5 million in funding from private investors.
Transaction Overview
Company Name
Announced On
6/11/2014
Transaction Type
Debt
Amount
$4,493,581
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6836 Bee Cave Rd. Building 3, 200
Austin, TX 78746
USA
Austin, TX 78746
USA
Phone
Website
Email Address
Overview
Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Neville
Chief Financial Officer
David Lowrance
Chief Operating Officer
Taneli Jouhikainen
VP - Bus. Development
Peter Ginsberg
VP - Finance
Michael Ciesla
VP - General Counsel
Kate McCabe
VP - Regulatory Affairs
Cecilia Ganslandt
VP - Regulatory Affairs
Mette Vinge
Browse more venture capital transactions:
Prev: 6/11/2014: Krux Digital venture capital transaction
Next: 6/11/2014: Core Informatics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs